Carbetocin

Carbetocin is a real, long-acting oxytocin analog used worldwide to prevent postpartum hemorrhage — approved in Canada, the UK, the EU and many other countries since the late 1990s, and notably still not FDA-approved in the US as of this review.

A longer-acting oxytocin

Carbetocin is a synthetic, long-acting analog of oxytocin, binding the same oxytocin receptor but with a half-life of roughly 40-60 minutes versus oxytocin's few minutes — long enough for a single injection to do the job that oxytocin normally requires a continuous infusion for. It's used immediately after childbirth to help the uterus contract and prevent postpartum hemorrhage, the leading cause of maternal death worldwide.

The evidence, including a nearly-30,000-patient trial

An early placebo/comparator trial (Dansereau et al., Am J Obstet Gynecol 1999, PMID 10076146) compared carbetocin to oxytocin after cesarean section in 694 patients and found less need for additional uterotonic intervention with carbetocin. Far larger and more recent: the WHO-led CHAMPION trial (Widmer et al., N Engl J Med 2018, PMID 30134138), which randomized nearly 30,000 women across 10 countries to a heat-stable formulation of carbetocin or standard oxytocin immediately after vaginal birth. Heat-stable carbetocin was non-inferior to oxytocin for the primary outcome (blood loss of 500mL or more, or need for additional uterotonics) — though the trial was underpowered to confirm non-inferiority for the rarer, more severe outcome of blood loss of 1,000mL or more, an honest limit on how far the "non-inferior" finding extends.

Why it isn't approved in the US

Carbetocin (branded as Pabal or Duratocin) has been approved in Canada since 1997, in the UK since 1997, and in the EU, Australia, and more than 20 other countries since, for postpartum hemorrhage prevention. As of this review, we found no evidence of an FDA approval or pending FDA filing for this indication in the US. A related but distinct product — intranasal carbetocin (a different formulation, developed for Prader-Willi syndrome hyperphagia, not postpartum hemorrhage) — received a Complete Response Letter from the FDA; that's a separate drug development program and shouldn't be confused with the postpartum-hemorrhage indication covered here.

The heat-stable, global-health version

A heat-stable formulation of carbetocin — stable without refrigeration, developed through a WHO/Ferring/Merck for Mothers public-private partnership — was added to the WHO Essential Medicines List following the CHAMPION trial, specifically for use in low-resource settings where oxytocin's cold-chain requirements can't be reliably maintained. This is a genuinely different story from most drugs on this site: carbetocin's main current relevance is global maternal-health access, not US regulatory status.